Stocks › CYTK
Cytokinetics, Incorporated (CYTK) stock analysis
WEAK BUY 27% confidence · analysed Oct 14, 2026
On Oct 14, 2026, our model rated Cytokinetics, Incorporated (CYTK) WEAK BUY with 27% confidence at a price of $61.62. That means the signals lean positive, but they are mixed, so conviction is low.
Technical picture
The 14-day RSI is 31. Momentum is soft: below the neutral 50 line, but not yet oversold.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price is below both its 50-day and 200-day moving averages, the classic picture of a downtrend.
Volume is about normal (0.8x the 20-day average).
Trend structure and money flow
Market structure: bullish structure intact, no fresh break.
The most recent swing high is $88.31 and the swing low is $58.43; traders often treat these as resistance and support.
Price is sitting in a bearish order block, a zone where large sellers stepped in before, so upside may stall here.
Fundamentals
The company reports a profit margin of 0.0% and revenue growth of -57.1%.
In its latest quarter it earned $-1.50 per share, which beat the $-1.60 analysts expected, with revenue -57.1% year over year.
Wall Street's average rating is 1.5 on a 1 (strong buy) to 5 (sell) scale, roughly a "strong buy", with an average price target of $109.95.
The next earnings report is expected around Nov 4, 2026; prices often move sharply around earnings.
Trade plan from the model
The model's long / bullish plan uses an entry near $63.14, a target of $67.32 (+6.6%) and a stop-loss at $59.00 (-6.6%).
That is a reward-to-risk ratio of about 1.0 to 1: the potential gain is not much bigger than the loss, so the setup is marginal.
The plan has a time limit: reassess by Oct 24, 2026 whatever the price does.
Research notes
CYTK’s bull case rests on strong early MYQORZO adoption—Q2 sales reached $25.3 million, well above consensus—and positive Phase 3 ACACIA-HCM data supporting aficamten’s expansion into non-obstructive hypertrophic cardiomyopathy. The bear case is execution and valuation risk: Cytokinetics remains unprofitable with heavy spending, negative equity, reliance on a limited cardiomyopathy portfolio, and competition from Bristol Myers Squibb’s Camzyos. The major recent catalyst is new ACACIA-HCM data presented October 12 showing improved exercise performance without new safety signals, while investors also await a planned Q4 supplemental filing and a November 14 PDUFA decision tied to label expansion. Analysts remain broadly bullish—18 of 20 covering firms rate the stock Buy, with a $106.06 average target versus roughly $61.62 currently—but UBS recently reduced its target to $104 on valuation concerns.
The model's one-paragraph read
Leans BUY — composite score +0.27 (WEAK BUY). Technicals: RSI 31.48, MACD bullish, price below SMA50. Fundamentals: margin 0.0%, revenue growth -57.1%. Financial results: YoY revenue -57.1%, last EPS surprise +6.3%, next earnings 2026-11-04. Smart Money Concepts: bullish structure intact, no fresh break, price retesting a bearish order block. FinGPT news read: positive. Internet research: CYTK’s **bull case** rests on strong early MYQORZO adoption—Q2 sales reached $25.3 million, well above consensus—and positive Phase 3 ACACIA-HCM data supporting aficamten’s expansion into non-obstructive hypertrophic cardiomyopathy. The **bear case** is execution and valuation risk: Cytokinetics remains unprofitable with heavy spending, negative equity, reliance on a limited cardiomyopathy portfolio, and competition from Bristol Myers Squibb’s Camzyos. The major recent catalyst is new ACACIA-HCM data presented October 12 showing improved exercise performance without new safety signals, while investors also await a planned Q4 supplemental filing and a November 14 PDUFA decision tied to label expansion. Analysts remain broadly bullish—18 of 20 covering firms rate the stock Buy, with a $106.06 average target versus roughly $61.62 currently—but UBS recently reduced its target to $104 on valuation concerns. Suggested levels: entry $63.14, target $67.32, stop-loss $59.0, exit by 2026-10-24 (10-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).
Past ratings for CYTK
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 14, 2026 | WEAK BUY | 27% | $61.62 | — |
"Move since" compares each call's price with the latest analysed price.
Other Healthcare stocks we cover
DVA · ETON · EVH · FTRE · HALO · HUM · IART · IBRX · ICLR · IRWD · JNJ · KMDA
Frequently asked questions
Is CYTK a buy right now?
As of Oct 14, 2026, our automated model rates Cytokinetics, Incorporated (CYTK) WEAK BUY with 27% confidence: the signals lean positive, but they are mixed, so conviction is low. This is a model output for education, not personal investment advice.
What is the price target for CYTK?
The model's most recent plan targets $67.32 with a stop-loss at $59.00, from an entry near $63.14.
When does Cytokinetics, Incorporated report earnings next?
The next earnings report is expected around Nov 4, 2026.
What does a WEAK BUY rating mean?
A WEAK BUY rating means the signals lean positive, but they are mixed, so conviction is low.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.